UpdateBot: robot: Update article (please report if you notice any mistake or error in this edit)

2022-06-10T08:07:02Z

robot: Update article (please report if you notice any mistake or error in this edit)

imported>DaxServer: Add back cat per discussion WP:TCAT using Pywikibot category add

2021-08-22T15:37:55Z

Add back cat per discussion WP:TCAT using Pywikibot category add

New page

{{Short description|Indian multinational pharmaceutical company}}
{{Use dmy dates|date=October 2017}}
{{Infobox company
| name = Sun Pharmaceutical Industries Limited
| logo = Sun Pharma logo.svg
| logo_size = 175px
| type = [[Public company|Public]]
| traded_as = {{Unbulleted list|{{BSE|524715}}|{{NSE|SUNPHARMA}}|
[[BSE SENSEX|BSE SENSEX Constituent]]|[[NIFTY 50|NSE NIFTY 50 Constituent]]}}
| ISIN = INE044A01036
| area_served = Worldwide
| key_people = [[Dilip Shanghvi]] (CEO)
| industry = [[Pharmaceutical industry|Pharmaceuticals]]
| products = {{hlist|[[Pharmaceutical]]s |[[generic drug]]s |[[over-the-counter drug]]s |[[vaccine]]s |[[Medical diagnosis|diagnostics]] |[[contact lens]]es |[[Veterinary medicine|animal health]] }}
| revenue = {{profit}} {{INRConvert|334.73|b}} (2020)<ref name=finance>{{cite web|url=https://www.sunpharma.com/sites/default/files/annual/SunPharmaAR2019-20.pdf|title=Sun Pharmaceutical Annual Report 2020|publisher=Sun Pharmaceutical Limited|access-date=2 July 2019}}</ref>
| operating_income = {{profit}} {{INRConvert|50.10|b}} (2020)<ref name=finance/>
| net_income = {{profit}} {{INRConvert|37.65|b}} (2020)<ref name=finance/>
| assets = {{profit}} {{INRConvert|682.52|b}} (2020)<ref name=finance/>
| equity = {{profit}} {{INRConvert|491.25|b}} (2020)<ref name=finance/>
| owner =
| num_employees = 36,000 (2020)<ref name=finance/>
| homepage = {{URL|http://www.sunpharma.com}}
| founder = [[Dilip Shanghvi]]
| foundation = {{start date and age|1983}}
| location_city = [[Mumbai]], [[Maharashtra]]
| location_country = India
| footnotes = <ref name="fy2018">{{cite web|url=http://www.sunpharma.com/sites/default/files/SPLL-Financial-Statement-17-18.pdf |title=Sun Pharmaceutical Announces Fourth Quarter and Fiscal Year 2018 Results |publisher=Sun Pharmaceutical |website=sunpharma.com |date=February 4, 2019 |access-date=February 4, 2019}}</ref>
}}

'''Sun Pharmaceutical Industries Limited''' ([[Trade name|d/b/a]] Sun Pharma) is an [[India]]n [[Multinational corporation|multinational]] [[pharmaceutical]] company headquartered in [[Mumbai, Maharashtra]], that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. Sun Pharma has presence in more than 100 countries across the globe.<ref>{{Cite web|last=Banerjee|first=Avishek|title=Sun Pharma: Global Is Local|url=http://businessworld.in/article/Sun-Pharma-Global-Is-Local/27-12-2018-165598|access-date=2021-08-06|website=BW Businessworld|language=en}}</ref> It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world,<ref name="Business Standard India">{{Cite news|title=Sun Pharmaceuticals Industries Ltd.|work=Business Standard India|url=https://www.business-standard.com/company/sun-pharma-inds-4325/information/company-history|access-date=2021-08-06}}</ref> with a total revenue of over US$4.5 billion as of June 2021.<ref name="Sun Pharma Industries">{{Cite web|title=Sun Pharma Industries|url=https://www.forbes.com/companies/sun-pharma-industries/|access-date=2021-08-06|website=Forbes|language=en}}</ref> The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.<ref name="Business Standard India"/> Its API products include Acamprosate Calcium, Alendronate Sodium, Amifostine trihydrate, Budensonide and Carvedilol.<ref>{{Cite web|title=Sun Pharma {{!}} IBEF|url=https://www.ibef.org/industry/research-development-india/showcase/sun-pharma|access-date=2021-08-06|website=www.ibef.org}}</ref>

==History==

Sun Pharmaceuticals was founded by [[Dilip Shanghvi]] in 1983 in [[Vapi]], [[Gujarat]], with five products to treat [[psychiatry]] ailments. Cardiology products were introduced in 1987<ref name="sunpharma.com">{{Cite web|title=Milestones & Recognitions {{!}} Sun Pharmaceutical Industries Limited|url=https://sunpharma.com/milestones-recognitions/|access-date=2021-08-06|website=Sun Pharmaceutical Industries Ltd.|language=en-US}}</ref> followed by [[gastroenterology]] products in 1989. Today it is ranked No.1 by prescriptions with 9 different classes of doctors in<ref>{{Citation|title=Strategic solutions|date=2013-01-11|url=http://dx.doi.org/10.4324/9780080938486-27|work=Hospitality Marketing|pages=210–219|publisher=Routledge|isbn=978-0-08-093848-6|access-date=2021-08-06}}</ref> India and a market leader in cardiology, gastroenterology, ortho, diabetology, dermatology, urology, and vitamins / minerals / nutrients.<ref>{{Citation|last=Katja S|first=Ziegler|title=AWACS I (Ger)|date=April 2019|url=http://dx.doi.org/10.1093/law-mpeccol/e542.013.542|work=Max Planck Encyclopedia of Comparative Constitutional Law|publisher=Oxford University Press|access-date=2021-08-06}}</ref>

The 2014 acquisition of [[Ranbaxy]] made Sun Pharma the largest [https://www.enrico.co.in/ pharma company] in India, the largest Indian pharma company in the US, and the 4th<ref name="Business Standard India"/> largest specialty generic company globally.

Over 72% of Sun Pharma sales are from markets outside India, primarily in the United States. The US is the single largest market, accounting for about 30% of the company's turnover;<ref>{{Cite web|title=US business remains Sun Pharma’s weak spot|url=https://www.fortuneindia.com/enterprise/us-business-remains-sun-pharmas-weak-spot/101421|access-date=2021-08-06|website=www.fortuneindia.com|language=en}}</ref> in all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is across 44 globally across across India, the US, Asia, Africa, Australia and Europe. In the United States, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. [[Food and Drug Administration]] (FDA).<ref>{{Cite web |url=http://www.sunpharma.com/sites/all/themes/sunpharma/images/annual/SPIL%20Feb14%20IR%20Presentation.pdf |title=Archived copy |access-date=10 April 2014 |archive-url=https://web.archive.org/web/20140413142558/http://www.sunpharma.com/sites/all/themes/sunpharma/images/annual/SPIL%20Feb14%20IR%20Presentation.pdf |archive-date=13 April 2014 |url-status=dead |df=dmy-all }}</ref>

Sun Pharma was listed on the stock exchange in 1994 in an issue oversubscribed 55 times. The founding family continues to hold a majority stake in the company.<ref>{{Cite journal|date=March 2019|title=Galaxy Surfactants: financial results for the quarter and nine months ended 31 Dec 2018|url=http://dx.doi.org/10.1016/j.fos.2019.03.069|journal=Focus on Surfactants|volume=2019|issue=3|pages=6|doi=10.1016/j.fos.2019.03.069|issn=1351-4210}}</ref>

Sun Pharma requested USFDA to withdraw approval for 28 Abbreviated New Drug Applications (ANDAs) belonging to its wholly owned subsidiary Ranbaxy Laboratories.<ref>{{Cite news|url=http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-announces-voluntary-withdrawals-of-28-andas/articleshow/56076088.cms|title=sun pharma announce withdraw anda|date=20 December 2016|access-date=22 December 2016|via=economic times}}</ref>

==Acquisitions and Joint Ventures==

Sun Pharma has complemented growth with select acquisitions over the last two decades. In 1996, Sun purchased a bulk drug manufacturing plant at [[Ahmednagar]] from [[Knoll Pharmaceuticals]] and MJ Pharma's dosage plant at Halol that are both U.S. FDA approved today. In 1997, Sun Pharma acquired Tamil Nadu Dadha Pharmaceuticals Limited (TDPL) based in [[Chennai]], mainly for their extensive [[gynaecology]] and [[oncology]] brands. Also in 1997, Sun Pharma initiated their first foray into the lucrative US market with the acquisition of Caraco Pharmaceuticals, based in [[Detroit]].

In 1998, Sun acquired a number of respiratory brands from [[Natco Pharma]]. Other notable acquisitions include Milmet Labs and Gujarat Lyka Organics (1999), Pradeep Drug Company (2000), Phlox Pharma (2004), a formulation plant at Bryan, Ohio and ICN, Hungary from Valeant Pharma and Able Labs (2005), and Chattem Chemicals (2008). In 2010, the company acquired a large stake in [[Taro Pharmaceuticals]],<ref>{{cite web|url=http://www.tarousa.com/|title=USA – Taro Pharmaceutical Industries|website=Tarousa.com|access-date=19 July 2018}}</ref> amongst the largest generic dermatology companies in the US, with operations across Canada and Israel. The company currently owns ~ 69% stake in Taro, for about $260 million.<ref>{{cite web|url=http://www.sunpharma.com/Acquisition.do|title=Corporate Website: Acquisitions|website=Sunpharma.com|access-date=19 July 2018|archive-url=https://web.archive.org/web/20110810182940/http://www.sunpharma.com/Acquisition.do|archive-date=10 August 2011|url-status=dead|df=dmy-all}}</ref>

In 2011, Sun Pharma entered into a joint venture with MSD to bring complex or differentiated generics to emerging markets (other than India).<ref>{{Cite news|title=Sun Pharmaceutical, Merck & Co call off 2011 JV: Sources|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharmaceutical-merck-co-call-off-2011-jv-sources/articleshow/45154170.cms?from=mdr|access-date=2021-08-06}}</ref>

In 2012, Sun announced acquisitions of two US companies: [[DUSA Pharmaceuticals]],<ref>{{cite web|url=http://in.reuters.com/article/dusa-sunpharma-idINDEE8A70AL20121108|title=Sun Pharma to buy U.S.-based Dusa for $230 mln|work=Reuters India|access-date=2 July 2015}}</ref> a dermatology device company; and generic pharma company URL Pharma <ref>{{cite web|url=http://www.takeda.com/news/2012/20121218_5405.html|title=Takeda to Sell Non-Colcrys URL Pharma, Inc. Generic Business to Sun Pharmaceutical|author=Takeda Pharmaceutical Company Limited|website=Takeda.com|access-date=2 July 2015}}</ref> In 2013, the company announced an R&D joint venture for ophthalmology with the research company, [[Intrexon]].<ref>{{cite web|url=http://investors.dna.com/phoenix.zhtml?c=249599&p=irol-newsArticle&ID=1860186&highlight=|title=Investors – Newsroom – Intrexon|website=Investors.dna.com|access-date=2 July 2015|archive-url=https://archive.today/20140410125413/http://investors.dna.com/phoenix.zhtml?c=249599&p=irol-newsArticle&ID=1860186&highlight=|archive-date=10 April 2014|url-status=dead|df=dmy-all}}</ref>

On 6 April 2014, Sun Pharma acquired Ranbaxy in a US$4 billion landmark transaction to create the world’s 5th largest specialty generic pharmaceutical company.<ref>{{Cite news|last=Reporter|first=B. S.|date=2014-04-08|title=Sun Pharma buys Ranbaxy from Japan's Daiichi|work=Business Standard India|url=https://www.business-standard.com/article/companies/sun-pharma-buys-ranbaxy-from-japan-s-daiichi-114040700737_1.html|access-date=2021-08-06}}</ref>

Then Sun Pharma entered into a licensing agreement with Merck & Co. Inc. for Tildrakizumab (MK- 3222) in order to further strengthen the specialty product pipeline.<ref>{{Cite news|title=Sun Pharma, Merck & Co Inc enter into pact for Tildrakizumab|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-merck-co-inc-enter-into-pact-for-tildrakizumab/articleshow/42730781.cms?from=mdr|access-date=2021-08-06}}</ref>

To access sterile injectable capacity in the US, it acquired Pharmalucence in the USA in the same year.<ref>{{Cite web|last=Unnikrishnan|first=C. H.|date=2014-07-16|title=Sun Pharma acquires US injectables firm Pharmalucence|url=https://www.livemint.com/Companies/hBDNNuOdQnSzaO9hWqHimK/Sun-Pharma-buys-USbased-Pharmalucence.html|access-date=2021-08-06|website=mint|language=en}}</ref>

In December 2014, the Competition Commission of India approved Sun Pharma's $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.<ref>{{cite web|url=http://in.reuters.com/article/ranbaxy-lab-sun-pharma-regulator-idINKBN0JM1AY20141209|title=CCI clears Sun Pharma-Ranbaxy deal|work=Reuters India|access-date=2 July 2015}}</ref><ref name="auto">{{cite web|url=http://in.reuters.com/article/gsk-sun-pharma-deals-idINL4N0W520E20150303|title=UPDATE 1-India's Sun Pharma to buy Glaxo's opiates business in Australia|work=Reuters India|access-date=2 July 2015}}</ref>

In March 2015, Sun Pharma announced it had agreed to buy GlaxoSmithKline's opiates business in Australia to strengthen its pain management portfolio.<ref name="auto" />

The following year Sun Pharma made some significant acquisitions, including 14 brands from Novartis in Japan to enter the Japanese market.<ref>{{Cite web|last=Bureau|first=Our|title=Sun Pharma acquires Novartis brands in Japan for $293 million|url=https://www.thehindubusinessline.com/companies/sun-pharma-acquires-novartis-brands-in-japan-for-293-million/article8410174.ece|access-date=2021-08-06|website=@businessline|language=en}}</ref>

It acquired Ocular Technologies, Sarl to strengthen its branded ophthalmic portfolio and also acquired Biosintez to enhance its presence in the Russian market.<ref name="Business Standard India"/>

From 2016 to 2018, Sun Pharma launched some of its new products in the USA.<ref name="sunpharma.com"/> It launched its first branded ophthalmic product, BromSite™ in 2016.<ref>{{Cite web|last=Monday|last2=November 28|last3=Tweet|first3=2016|title=Sun Pharma Launches First Branded Ophthalmic Product in U.S.|url=http://www.ophthalmologyweb.com/1315-News/330803-Sun-Pharma-Launches-First-Branded-Ophthalmic-Product-in-U-S/|access-date=2021-08-06|website=www.ophthalmologyweb.com|language=en}}</ref> In 2017, the company launched its speciality product Odomzo.<ref>{{Cite web|last=Trivedi|first=Isha|date=2016-12-22|title=Sun Pharma to acquire Novartis’s cancer drug Odomzo for $175 mn|url=https://www.livemint.com/Companies/0dD50eq5zcAuTg60uB1qUM/Sun-Pharma-to-acquire-Novartiss-cancer-drug-Odomzo-for-175.html|access-date=2021-08-06|website=mint|language=en}}</ref> and then in 2018 another specialty product ILUMYA™ (tildrakizumab-asmn) was launched to treat moderate-to-severe plaque psoriasis.<ref>{{Cite web|last=Medha|date=2018-10-25|title=New drug launched for moderate-to-severe plaque psoriasis|url=https://speciality.medicaldialogues.in/new-drug-launched-for-moderate-to-severe-plaque-psoriasis|access-date=2021-08-06|website=speciality.medicaldialogues.in|language=en}}</ref>

In 2019, Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence.<ref>{{Cite web|date=2018-11-27|title=Sun Pharma to acquire Japan's Pola Pharma for $1 mn; to strengthen presence in dermatology segment-Business News , Firstpost|url=https://www.firstpost.com/business/sun-pharma-to-acquire-japans-pola-pharma-for-1-mn-to-strengthen-presence-in-dermatology-segment-5619901.html|access-date=2021-08-06|website=Firstpost}}</ref> The company entered the Greater China market by partnering with China Medical System Holdings.<ref>{{Cite web|last=www.ETHealthworld.com|title=Sun Pharma arm enters pact with China Medical System - ET HealthWorld|url=https://health.economictimes.indiatimes.com/news/pharma/sun-pharma-arm-enters-pact-with-china-medical-system/69982236|access-date=2021-08-06|website=ETHealthworld.com|language=en}}</ref> And it launched a speciality product Cequa in the United States for the treatment of dry eyes.<ref>{{Cite web|title=Sun Pharma Launches Cequa for the Treatment of Dry Eye Disease in the US|url=https://eyewire.news/articles/sun-pharma-launches-cequa-for-the-treatment-of-dry-eye-disease-in-the-us/|access-date=2021-08-06|website=Eyewire News|language=en-US}}</ref>

==SPARC==
In 2007, Sun Pharma demerged its innovative R&D arm, and listed it separately on the stock market as the Sun Pharma Advanced Research Company Ltd. ({{NSE|SPARC}}, {{BSE|532872}}). In 2013, SPARC declared revenue of ₹873 million.<ref>{{cite web|url=http://www.moneycontrol.com/financials/sunpharmaadvancedresearchcompany/profit-loss/SPA#SPA|title=Sun Pharma Advanced Research Company Profit & Loss account, Sun Pharma Advanced Research Company Financial Statement & Accounts|website=Moneycontrol.com|access-date=2 July 2015}}</ref> SPARC focuses on new chemical entities (NCE) research and new drug delivery systems and offers an annual update<ref>{{Cite web |url=http://www.sunpharma.in/SPARC%20Investor%20Update%20Feb%2026%202014.pdf |title=Archived copy |access-date=10 April 2014 |archive-url=https://web.archive.org/web/20140413143947/http://www.sunpharma.in/SPARC%20Investor%20Update%20Feb%2026%202014.pdf |archive-date=13 April 2014 |url-status=dead |df=dmy-all }}</ref> of its pipeline (NDDS).<ref>{{cite web|url=http://sunpharma.in/index.htm|title=SUN PHARMA ADVANCED RESEARCH COMPANY|website=Sunpharma.in|access-date=2 July 2015}}</ref>

==Awards ==
Sun Pharma stood second in the [[India's Most Reputed Brands]] (Pharmaceutical) list <ref>{{Cite web |url=http://economictimes.indiatimes.com/pharma/lupinsun-pharma-and-cipla-amongst-tops-most-reputed-pharma-brand-list/articleshow/53742154.cms |title=Archived copy |access-date=18 August 2016 |archive-url=https://web.archive.org/web/20160820160335/http://economictimes.indiatimes.com/pharma/lupinsun-pharma-and-cipla-amongst-tops-most-reputed-pharma-brand-list/articleshow/53742154.cms |archive-date=20 August 2016 |url-status=dead |df=dmy-all }}</ref> in a study conducted by BlueBytes,<ref>{{cite web|url=http://www.bluebytes.info|title=Blue Bytes|website=Bluebytes.info|access-date=19 July 2018}}</ref> a leading Media Analytics firm in association with TRA Research,<ref>{{cite web|url=http://www.trustadvisory.info|title=TRA|website=Trustadvisory.info|access-date=19 July 2018}}</ref> a brand insights organization (both a part of the Comniscient Group).

'''2019:'''

1.Listed among the Forbes World’s Best Regarded companies"<ref name="Sun Pharma Industries"/>

2. CSR subsidiary Foundation for Disease Elimination and Control of India conferred with Mahatma Award for Social Good 2019<ref>{{Cite web|title=2019 Recipients|url=https://www.mahatmaaward.com/india-2019|access-date=2021-08-06|website=Mahatma Award|language=en}}</ref>

3. Mobile Healthcare Unit project recognised as the Best Public Health Initiative by ACEF Asian Leadership Forum<ref>{{Cite web|title=ACEF-Asian Leaders Forum and Awards|url=https://www.customerengagement.asia/winners/2019_September.html|access-date=2021-08-06|website=www.customerengagement.asia}}</ref>

'''2020:'''

1. Listed among the Forbes World’s Best Employers 2020<ref>{{Cite web|title=The World's Best Employers 2020|url=https://www.forbes.com/lists/worlds-best-employers/|access-date=2021-08-06|website=Forbes|language=en}}</ref>

2. Volini named in Nielsen BASES Top Breakthrough Innovation Winners India 2020 list<ref>{{Cite web|title=Radhika Joshi on LinkedIn: #BASES #innovation #breakthroughinnovations {{!}} 28 comments|url=https://www.linkedin.com/posts/radhika-joshi-1214851a_bases-innovation-breakthroughinnovations-activity-6744605462500560896-Xa4W|access-date=2021-08-06|website=www.linkedin.com|language=en}}</ref>

==References==
{{Reflist}}

==External links==
*{{Official website|http://www.sunpharma.com}}

{{Nifty 200 companies}}
{{BSE Sensex}}
{{S&P CNX Nifty companies}}
{{Authority control}}

[[Category:Sun Pharma| ]]
[[Category:BSE SENSEX]]
[[Category:Companies based in Mumbai]]
[[Category:Indian brands]]
[[Category:Pharmaceutical companies of India]]
[[Category:Vaccine producers]]
[[Category:NIFTY 50]]
[[Category:Indian companies established in 1983]]
[[Category:1983 establishments in Gujarat]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]

Sun Pharma - Revision history

UpdateBot: robot: Update article (please report if you notice any mistake or error in this edit)

imported>DaxServer: Add back cat per discussion WP:TCAT using Pywikibot category add